Engineering TCR-preserved allogeneic CAR-T cells: leveraging cancer immune evasion principles to establish T-cell tolerance



Summary

Engineering allogeneic CAR-T cells that retain their T cell receptor (TCR) could overcome challenges of current CAR-T therapies. By understanding how cancer cells evade immune responses, researchers aim to engineer CAR-T cells that induce tolerance. This involves strategies like mimicking immune checkpoints or expressing immunosuppressive molecules. The goal is to create “TCR-preserved” allogeneic CAR-T cells that can recognize and eliminate cancer cells while avoiding graft-versus-host disease (GVHD) and potentially achieving long-term persistence. This innovative approach leverages cancer’s own immune evasion tactics to establish a state of T-cell tolerance, paving the way for safer and more effective off-the-shelf CAR-T therapies.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!